

**VYEPTI® (EPTINEZUMAB-JJMR)
PRESCRIBER ORDER FORM**



Fax completed form, insurance information, and clinical documentation to:

Warren, MI t 888-386-0886 f 586-263-3306

| | |
|---------------|----------------|
| Patient Name: | Date of Birth: |
|---------------|----------------|

Address:

| | | | | | |
|--------|---------|---------------------------------|-----------------------------|---------|--|
| Phone: | Height: | <input type="checkbox"/> inches | <input type="checkbox"/> cm | Weight: | <input type="checkbox"/> lbs <input type="checkbox"/> kg |
|--------|---------|---------------------------------|-----------------------------|---------|--|

CLINICAL INFORMATION

| | |
|--------------------------------|--------------|
| Primary Diagnosis Description: | ICD-10 Code: |
|--------------------------------|--------------|

| | |
|--|---|
| Medications previously tried and failed (list medication and duration of use): | Has patient received Botox®? <input type="checkbox"/> Yes, # of injections: _____ <input type="checkbox"/> No |
|--|---|

PRESCRIPTION

For existing Vyepti patients: Date of last infusion: _____

Vyepti® (Eptinezumab-jjmr) refill as directed x 1 year

- Infuse 100 mg IV over 30 minutes once every 3 months
- Infuse 300 mg IV over 30 minutes once every 3 months

Using a 50ml NS IV bag, flush IV tubing with NS 10 to 20 mL after each infusion

Infuse via a 0.2 micron in-line filter

Dispense quantity sufficient of Vyepti® 100 mg single dose vials for each dose

ANCILLARY ORDERS

Anaphylaxis Kit

If this is a 1st dose, would you like Compassus to provide an anaphylaxis kit with the 1st dose?

- Yes No

- Dosage:
- Epinephrine 0.3 mg (> 30 kg), 0.15 mg (15 to 30 kg), or 0.01 mg/kg (< 15 kg) SQ or IM x 1; repeat x 1 in 5 to 15 min PRN.
 - Diphenhydramine 25mg PO or IV/IM. May repeat additionally 25mg PO or IV PRN.
 - Normal saline 500 mL (> 30 kg) or 250 mL (< 30 kg) IV at KVO rate PRN anaphylaxis. Patient < 30 kg, infuse over 2 to 4 hours PRN headache rated > 5 on pain scale.

Pre-Medication Orders

- Other: _____

IV Flush Orders

- Peripheral: NS 2 to 3 mL pre-/post-use.
- Implanted Port: NS 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed.
- Other: _____

Lab Orders

- No labs ordered at this time.
- Other: _____

Skilled nurse to initiate IV access for administration of doses in the home or alternate care setting. Access to be discontinued upon completion of infusion. Refill above ancillary orders as directed x 1 year.

I certify that the use of the indicated treatment is medically necessary and I will be supervising the patient's treatment.

Prescriber Signature: _____ **Date:** _____

PRESCRIBER INFORMATION

| | | |
|------------------|--------|------|
| Prescriber Name: | Phone: | Fax: |
|------------------|--------|------|

| | |
|----------|------|
| Address: | NPI: |
|----------|------|

| | | |
|--------------|------|-----------------|
| City, State: | Zip: | Office Contact: |
|--------------|------|-----------------|

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. **IMPORTANT WARNING:** This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.